发布求助
文献互助 智能选刊 最新文献

Skin therapy letter最新文献

筛选
英文 中文
More Than Skin Deep: Understanding the Skin-Bone Axis. 超越皮肤深层：理解皮肤-骨骼轴。
Skin therapy letter Pub Date : 2026-07-01
Santina Conte, Vu Le, Monica K Li
{"title":"More Than Skin Deep: Understanding the Skin-Bone Axis.","authors":"Santina Conte, Vu Le, Monica K Li","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The skin's role as a mirror of internal disease has long been established, with clear associations to several internal organs. However, its relationship with bone is less well known. There are clear physiological links between the two organ systems, with their shared factors crucial to maintain structural integrity and homeostasis. Collagen, vitamin D homeostasis, aging, medications, and the gut microbiome are all factors that impact both skin and bone. It is of utmost importance that the skin-bone axis be adequately understood to support a healthy aging process. In this review, we discuss the multiple facets related to skin and bone health, their interconnectivity, as well as the importance of promoting whole body health.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"31 4","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148760075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molluscum Contagiosum: A Review and Update on New Treatments. 传染性软疣：新治疗方法的回顾与进展。
Skin therapy letter Pub Date : 2026-07-01
Priyenka Khatiwada, Mariana Phillips
{"title":"Molluscum Contagiosum: A Review and Update on New Treatments.","authors":"Priyenka Khatiwada, Mariana Phillips","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"31 4","pages":"6-10"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148763397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Zasocitinib: New Frontier in Tyrosine Kinase 2 Inhibition. 扎索替尼：酪氨酸激酶2抑制的新领域。
Skin therapy letter Pub Date : 2026-05-01
Samantha R Adam, Maxwell Sauder
{"title":"Zasocitinib: New Frontier in Tyrosine Kinase 2 Inhibition.","authors":"Samantha R Adam, Maxwell Sauder","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Zasocitinib is a novel highly selective tyrosine kinase 2 (TYK2) inhibitor that is in late phase development for the treatment of psoriasis and psoriatic arthritis. This article will review its efficacy, safety and tolerability. Currently, deucravacitinib is the only TYK2 inhibitor with regulatory approval from most major authorities. Zasocitinib offers potential benefits, as it has higher target selectivity and affinity of the Janus homology 2 (JH2) domain of TYK2 as compared to deucravacitinib. This selectivity leads to minimal inhibition of Janus kinase (JAK) 1, JAK2 and JAK3 (JAK1-3), and therefore may result in less off-target effects that have been associated with other molecules.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"31 3","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148043815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exosomes in Dermatology. 皮肤病学中的外泌体。
Skin therapy letter Pub Date : 2026-05-01
Annabel Shen, Fyona Okundia, Stephen K Tyring
{"title":"Exosomes in Dermatology.","authors":"Annabel Shen, Fyona Okundia, Stephen K Tyring","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Exosomes are nanosized extracellular vesicles increasingly recognized as regulators of cutaneous biology with direct clinical relevance. In dermatology, they influence keratinocyte and fibroblast proliferation, pigmentation pathways, and immune modulation in disorders such as atopic dermatitis and cutaneous lupus. Their strongest evidence lies in wound healing, where exosomes accelerate closure by dampening proinflammatory cytokines (tumor necrosis factor-α, interleukin-6, matrix metalloproteinase-9), enhancing angiogenesis through vascular endothelial growth factor signaling, and improving collagen deposition and scar quality. Early studies also support their role in regenerative skin care, including reversal of photoaging, improved elasticity, and stimulation of hair follicle growth. Although current use is limited to cosmetic applications without United States Food and Drug Administration (FDA) approval, international experience suggests therapeutic potential in chronic wounds, inflammatory dermatoses, and pigmentation disorders. For clinicians, exosomes represent a novel biologic platform that may soon complement established therapies, underscoring the importance of ongoing translational research and regulatory clarity.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"31 3","pages":"4-7"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148043762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to: Deuruxolitinib for Alopecia Areata. Deuruxolitinib治疗斑秃。
Skin therapy letter Pub Date : 2026-04-30
Alexander Robbins, Mariana Phillips
{"title":"Erratum to: Deuruxolitinib for Alopecia Areata.","authors":"Alexander Robbins, Mariana Phillips","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"31 3","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Topical Ruxolitinib for the Treatment of Hidradenitis Suppurativa. 局部鲁索利替尼治疗化脓性汗腺炎。
Skin therapy letter Pub Date : 2026-03-01
Claire Fason, Stephen Tyring
{"title":"Topical Ruxolitinib for the Treatment of Hidradenitis Suppurativa.","authors":"Claire Fason, Stephen Tyring","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterized by painful nodules, abscesses, sinus tracts, and scarring, with significant impact on quality of life. Although biologics have expanded treatment options for moderate to severe disease, there are currently no approved therapies specifically indicated for mild HS. Emerging evidence implicates dysregulation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway in HS pathophysiology, suggesting JAK inhibition as a promising therapeutic strategy. This review summarizes current evidence on JAK inhibition in HS, with a focus on topical ruxolitinib. Early clinical trials in patients with mild to moderate HS have demonstrated encouraging efficacy, including significant improvements in Hidradenitis Suppurativa Clinical Response (HiSCR) rates and histologic reductions in epidermal and dermal inflammation, alongside a favorable safety profile. Existing data support topical ruxolitinib as a promising, targeted, and potentially safer treatment option for early-stage HS.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"31 2","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147469325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in the Management of Hyperhidrosis. 多汗症的治疗进展。
Skin therapy letter Pub Date : 2026-03-01
Morgan Parker, Mariana Phillips
{"title":"Advances in the Management of Hyperhidrosis.","authors":"Morgan Parker, Mariana Phillips","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Hyperhidrosis (HH), a condition characterized by excessive sweating beyond thermoregulation, significantly impairs quality of life. Conventional medications to treat HH include aluminum chloride hexahydrate, systemic anticholinergics, and botulinum toxin injections. New treatments have emerged including glycopyrronium bromide, sofpironium bromide, targeted alkali thermolysis, and microwave devices. This paper reviews the mechanism of action, efficacy, safety, and practical considerations associated with these treatments.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"31 2","pages":"4-7"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147469327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Icotrokinra: A Promising Oral IL-23 Receptor Inhibitor for Moderate-to-Severe Plaque Psoriasis. Icotrokinra：一种治疗中重度斑块型银屑病的口服IL-23受体抑制剂。
Skin therapy letter Pub Date : 2026-01-01
Fyona Okundia, Muna Shakhashiro, Stephen K. Tyring
{"title":"Icotrokinra: A Promising Oral IL-23 Receptor Inhibitor for Moderate-to-Severe Plaque Psoriasis.","authors":"Fyona Okundia, Muna Shakhashiro, Stephen K. Tyring","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Biologics have emerged in recent years as relatively safe and effective options for managing plaque psoriasis, however, a subset of patients remain reluctant to initiate biologic therapy. Icotrokinra is a novel, first-in-class oral peptide that targets the interleukin-23 receptor and has demonstrated a favorable safety and efficacy profile comparable to that of injectable biologics in individuals aged 12 years and older. This review summarizes the clinical trial data regarding the safety and efficacy of icotrokinra.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"31 1","pages":"4-7"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146012340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deuruxolitinib for Alopecia Areata. deurxolitinib治疗斑秃。
Skin therapy letter Pub Date : 2026-01-01
Alexander Robbins, Mariana Phillips
{"title":"Deuruxolitinib for Alopecia Areata.","authors":"Alexander Robbins, Mariana Phillips","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Alopecia areata (AA), an autoimmune condition characterized by non-scarring hair loss, affects 2% of the United States population. AA is a CD8 T-cell driven autoimmune disease in which the cytokines interferon-gamma and interleukin-15 play a central role in disease progression. These pathways depend on Janus kinase (JAK) signaling, making JAK inhibitors an ideal therapeutic option in treating AA. Deuruxolitinib, an oral JAK inhibitor, was approved by the US Food and Drug Administration in July 2024, for the treatment of severe AA in adults. Deuruxolitinib is the third oral JAK inhibitor approved for the treatment of severe AA, the others being baricitinib and ritlecitinib. Deuruxolitinib's mechanism of action, clinical efficacy, and safety profile in the treatment of AA are reviewed.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"31 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146012343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OX40 Ligand Inhibitors for Moderate-to-Severe Atopic Dermatitis: A Review of Phase II Clinical Trial Data. OX40配体抑制剂治疗中重度特应性皮炎：II期临床试验数据综述
Skin therapy letter Pub Date : 2025-11-01
Siddhartha Sood, Alim R Devani, Tiago Torres, Jensen Yeung, Vimal H Prajapati
{"title":"OX40 Ligand Inhibitors for Moderate-to-Severe Atopic Dermatitis: A Review of Phase II Clinical Trial Data.","authors":"Siddhartha Sood, Alim R Devani, Tiago Torres, Jensen Yeung, Vimal H Prajapati","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a common, chronic immune-mediated inflammatory skin disease. The OX40-OX40 ligand (OX40L) pathway has emerged as a novel therapeutic target. On this basis, three phase II clinical trials have been conducted to evaluate the efficacy and safety of three different OX40-OX40L inhibitors (amlitelimab, rocatinlimab, and telazorlimab) in moderate-to-severe AD. Herein, we review the published data from these studies.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 6","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145725944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书